Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jul;33(7):1095–1100. doi: 10.1128/aac.33.7.1095

In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.

K A McIntyre 1, J N Galgiani 1
PMCID: PMC176068  PMID: 2551215

Abstract

We used six candidal strains (two Candida albicans and one each of four other species) to study the effects of test conditions on the activity of SCH 39304 compared with that of fluconazole in broth macro- and microdilution assays. Increasing the inoculum from 10(2) to 10(5) yeasts per ml raised the MICs for all isolates up to greater than 512-fold. In contrast, results with a 50% turbidimetric endpoint (50% inhibitory concentration; IC1/2) varied no more than twofold. Similar effects were seen with fluconazole, and both drugs were found to have an associated delay in onset of action. Acidity was found to increase both MICs and IC1/2s. Other effects were observed among four synthetic media, but a consistent pattern was not identified. Incubation temperatures of 37, 35, and 30 degrees C yielded equivalent results. Broth microdilution IC1/2s against most of 40 isolates of C. albicans were 0.31 microgram/ml +/- fourfold for SCH 39304 and 0.16 microgram/ml +/- twofold for fluconazole. Treatment of experimental candidiasis in rats with SCH 39304 and fluconazole resulted in 50% effective doses of 0.33 and 0.49 mg/kg per day, respectively. In contrast, another C. albicans isolate, previously identified as resistant to other azoles, had IC1/2s of 20 micrograms of SCH 39304 per ml and, in vivo, a 50% effective dose of 2.25 mg/kg per day. We conclude that the in vivo efficacy of SCH 39304 correlates with MIC results when broth macrodilution testing is performed with a small inoculum and with IC1/2 results which are independent of inoculum size.

Full text

PDF
1095

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Block E. R., Bennett J. E. Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother. 1972 Jun;1(6):476–482. doi: 10.1128/aac.1.6.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Block E. R., Jennings A. E., Bennett J. E. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother. 1973 Oct;4(4):392–395. doi: 10.1128/aac.4.4.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Calhoun D. L., Galgiani J. N. Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother. 1984 Sep;26(3):364–367. doi: 10.1128/aac.26.3.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Doern G. V., Tubert T. A., Chapin K., Rinaldi M. G. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol. 1986 Oct;24(4):507–511. doi: 10.1128/jcm.24.4.507-511.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galgiani J. N., Stevens D. A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother. 1976 Oct;10(4):721–728. doi: 10.1128/aac.10.4.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Galgiani J. N., VanWyck D. B. Ornithyl amphotericin methyl ester treatment of experimental candidiasis in rats. Antimicrob Agents Chemother. 1984 Jul;26(1):108–109. doi: 10.1128/aac.26.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galgiant J. N., Stevens D. A. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother. 1978 Feb;13(2):249–254. doi: 10.1128/aac.13.2.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hoeprich P. D., Finn P. D. Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis. 1972 Oct;126(4):353–361. doi: 10.1093/infdis/126.4.353. [DOI] [PubMed] [Google Scholar]
  9. Horsburgh C. R., Jr, Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 1983 Jan 24;74(1B):23–29. doi: 10.1016/0002-9343(83)90511-9. [DOI] [PubMed] [Google Scholar]
  10. Johnson B., White R. J., Williamson G. M. Factors influencing the susceptibility of Candida albicans to the polyenoic antibiotics nystatin and amphotericin B. J Gen Microbiol. 1978 Feb;104(2):325–333. doi: 10.1099/00221287-104-2-325. [DOI] [PubMed] [Google Scholar]
  11. Jordan G. W., Hoeprich P. D. Susceptibility of three groups of Staphylococcus aureus to newer antimicrobial agents. Antimicrob Agents Chemother. 1977 Jan;11(1):7–12. doi: 10.1128/aac.11.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kobayashi G. S., Medoff G. Antifungal agents: recent developments. Annu Rev Microbiol. 1977;31:291–308. doi: 10.1146/annurev.mi.31.100177.001451. [DOI] [PubMed] [Google Scholar]
  13. MacKerrow S. D., Merry J. M., Hoeprich P. D. Effect of buffers on testing of Candida species susceptibility to flucytosine. J Clin Microbiol. 1987 May;25(5):885–888. doi: 10.1128/jcm.25.5.885-888.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Minagawa H., Kitaura K., Nakamizo N. Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother. 1983 Jan;23(1):105–107. doi: 10.1128/aac.23.1.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Normark S., Schönebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother. 1972 Sep;2(3):114–121. doi: 10.1128/aac.2.3.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shadomy S. In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun. 1971 Aug;4(2):143–148. doi: 10.1128/iai.4.2.143-148.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis. 1983 Jun;147(6):1070–1077. doi: 10.1093/infdis/147.6.1070. [DOI] [PubMed] [Google Scholar]
  20. Wong B., Bernard E. M., Gold J. W., Fong D., Silber A., Armstrong D. Increased arabinitol levels in experimental candidiasis in rats: arabinitol appearance rates, arabinitol/creatinine ratios, and severity of infection. J Infect Dis. 1982 Sep;146(3):346–352. doi: 10.1093/infdis/146.3.346. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES